These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 20072840

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Danusertib, an aurora kinase inhibitor.
    Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ.
    Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
    Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Blood; 2008 Apr 15; 111(8):4355-64. PubMed ID: 18268096
    [Abstract] [Full Text] [Related]

  • 4. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A, Balabanov S, Keller G, Panse J, Schafhausen P, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.
    Leuk Res; 2008 Dec 15; 32(12):1857-65. PubMed ID: 18514829
    [Abstract] [Full Text] [Related]

  • 5. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
    Fei F, Lim M, Schmidhuber S, Moll J, Groffen J, Heisterkamp N.
    Mol Cancer; 2012 Jun 21; 11():42. PubMed ID: 22721004
    [Abstract] [Full Text] [Related]

  • 6. Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
    Balabanov S, Gontarewicz A, Keller G, Raddrizzani L, Braig M, Bosotti R, Moll J, Jost E, Barett C, Rohe I, Bokemeyer C, Holyoake TL, Brümmendorf TH.
    PLoS One; 2011 Apr 26; 6(4):e19164. PubMed ID: 21541334
    [Abstract] [Full Text] [Related]

  • 7. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
    Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, van Noort C, Mariani M, Spinelli R, Carpinelli P, Laffranchi B, de Jonge MJ.
    J Clin Oncol; 2009 Oct 20; 27(30):5094-101. PubMed ID: 19770380
    [Abstract] [Full Text] [Related]

  • 8. Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
    Modugno M, Casale E, Soncini C, Rosettani P, Colombo R, Lupi R, Rusconi L, Fancelli D, Carpinelli P, Cameron AD, Isacchi A, Moll J.
    Cancer Res; 2007 Sep 01; 67(17):7987-90. PubMed ID: 17804707
    [Abstract] [Full Text] [Related]

  • 9. Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.
    Moore AS, Blagg J, Linardopoulos S, Pearson AD.
    Leukemia; 2010 Apr 01; 24(4):671-8. PubMed ID: 20147976
    [Abstract] [Full Text] [Related]

  • 10. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
    Mancini M, Corradi V, Petta S, Barbieri E, Manetti F, Botta M, Santucci MA.
    J Pharmacol Exp Ther; 2011 Mar 01; 336(3):596-604. PubMed ID: 21041536
    [Abstract] [Full Text] [Related]

  • 11. Aurora kinase inhibitors as anti-cancer therapy.
    Lok W, Klein RQ, Saif MW.
    Anticancer Drugs; 2010 Apr 01; 21(4):339-50. PubMed ID: 20016367
    [Abstract] [Full Text] [Related]

  • 12. Aurora kinases and their inhibitors: more than one target and one drug.
    Carpinelli P, Moll J.
    Adv Exp Med Biol; 2008 Apr 01; 610():54-73. PubMed ID: 18593015
    [Abstract] [Full Text] [Related]

  • 13. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
    Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, Moll J.
    Mol Cancer Ther; 2007 Dec 01; 6(12 Pt 1):3158-68. PubMed ID: 18089710
    [Abstract] [Full Text] [Related]

  • 14. Aurora kinases as targets for cancer therapy.
    Mountzios G, Terpos E, Dimopoulos MA.
    Cancer Treat Rev; 2008 Apr 01; 34(2):175-82. PubMed ID: 18023292
    [Abstract] [Full Text] [Related]

  • 15. Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
    Bosotti R, Carpinelli P, Healy S, Locatelli G, Cappella P, Lanfrancone L, Calogero R, Moll J, Isacchi A.
    Gene; 2012 Feb 25; 494(2):202-8. PubMed ID: 21914463
    [Abstract] [Full Text] [Related]

  • 16. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.
    Am J Hematol; 2012 Nov 25; 87(11):E125-8. PubMed ID: 23044928
    [Abstract] [Full Text] [Related]

  • 17. Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
    Fraedrich K, Schrader J, Ittrich H, Keller G, Gontarewicz A, Matzat V, Kromminga A, Pace A, Moll J, Bläker M, Lohse AW, Hörsch D, Brümmendorf TH, Benten D.
    Clin Cancer Res; 2012 Sep 01; 18(17):4621-32. PubMed ID: 22753592
    [Abstract] [Full Text] [Related]

  • 18. Bosutinib: a novel second-generation tyrosine kinase inhibitor.
    Isfort S, Keller-v Amsberg G, Schafhausen P, Koschmieder S, Brümmendorf TH.
    Recent Results Cancer Res; 2014 Sep 01; 201():81-97. PubMed ID: 24756786
    [Abstract] [Full Text] [Related]

  • 19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov 01; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 20. Aurora kinases as anticancer drug targets.
    Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Gandara DR.
    Clin Cancer Res; 2008 Mar 15; 14(6):1639-48. PubMed ID: 18347165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.